{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"49","upperLimit":"78.4","value":"62"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"48"}],"units":"Participants"}],"description":"Time from infusion to the first of event or censoring Events = Relapse, No Response (including CR/CRi without B Cell Aplasia), or Death; Censoring =Initiation of New Anticancer Therapy, Last Day of Follow-up/EOS; whichever occurs first.","dispersionType":"95% Confidence Interval","groups":[{"description":"Poor Response to Prior B Cell Directed Engineered cell therapy","id":"OG000","title":"Cohort B"}],"paramType":"NUMBER","reportingStatus":"POSTED","timeFrame":"1 year","title":"Number of Subjects With Event-Free Survival in Patients With Poor Response to Prior B Cell Directed Engineered Cell Therapy 1 Year After Treatment.","type":"PRIMARY","unitOfMeasure":"percentage of subject"}